ATHE
Alterity Therapeutics Limited
There isn't enough reported data to score ATHE yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ATHE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ATHE's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATHE PE Valuation
ATHE has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ATHE Forward outlook
There aren't enough analyst estimates for ATHE to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ATHE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$0.13 | +$0.23 |
ATHE and LLY do not have enough comparable growth data to identify a winner.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ATHE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $1M | -45% |
| Q4 2022 | $1.6M | +1.1% |
| Q2 2022 | $1.9M | +13% |
| Q4 2021 | $1.6M | +23% |
| Q4 2020 | $1.3M | +3.7% |
| Q4 2019 | $1.3M | -24% |
| Q2 2019 | $1.7M | +1155% |
| Q2 2018 | $137.7K | -84% |
ATHE's revenue is growing: $1M last quarter, down 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -508% | -106 points |
| Q4 2022 | -451% | -5.7 points |
| Q2 2022 | -378% | N/A |
| Q4 2021 | -279% | +31 points |
| Q2 2021 | -402% | -121 points |
| Q4 2020 | -445% | -214 points |
| Q4 2019 | -310% | -91 points |
| Q2 2019 | -281% | -63 points |
ATHE's operating margin was −508% last quarter, down 106 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ATHE in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ATHE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2024 | -$8.6M | -$4.4M |
| Q2 2023 | -$4.2M | -$4M |
| Q4 2022 | -$3.5M | +$2.4M |
| Q2 2022 | -$236.2K | +$11.6M |
| Q4 2021 | -$5.9M | -$918.5K |
| Q2 2021 | -$11.9M | -$7.2M |
| Q4 2020 | -$5M | -$3.2M |
| Q2 2020 | -$4.7M | -$80.6K |
ATHE has burned cash in almost every quarter: −$17M over the past year, against −$28M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ATHE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +75% | +2.7B shares |
| 1 year | +159366% | +6.4B shares |
| 3 years | +11882% | +6.3B shares |
| 5 years | +952204% | +6.4B shares |
| Available history | +1686795% | +6.4B shares |
ATHE has 6.4B diluted shares, up 159366% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q2 2021 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ATHE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ATHE Net Leverage
ATHE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ATHE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.3 | Oversold |
| Stochastic | 7.2 | Oversold |
ATHE's weekly RSI is 29 (oversold) and its Stochastic is 7 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ATHE PE vs Healthcare Sector
ATHE has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ATHE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.70 | 22% below |
| 20 week MA | $3.86 | 46% below |
| 50 week MA | $3.80 | 45% below |
| 100 week MA | $3.98 | 47% below |
| 200 week MA | $3.12 | 33% below |
ATHE is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ATHE on trend strength, trading above more of its moving averages.
ATHE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.40 | $14.5 | +73% |
| 2021 | $14.5 | $8.20 | -43% |
| 2022 | $8.20 | $3.00 | -63% |
| 2023 | $3.00 | $2.49 | -17% |
| 2024 | $2.49 | $3.14 | +26% |
| 2025 | $3.14 | $3.17 | +1% |
| 2026 YTD | $3.17 | $2.10 | -34% |
ATHE has finished lower in three of the last six years. It's down 34% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ATHE on returns for 2026, with the stronger performance.